Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596073 · ClinicalTrials.gov registry record · Phase 1
Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT03596073: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT03596073 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03596073, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This research study is studying a topical ointment called calcipotriene to see if it can stimulate the immune cells against the breast lesion in ways that would prevent its recurrence after surgical removal
Interventions
- DRUG Topical Calcipotriene Ointment
- OTHER Topical Vaseline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596073
The ClinicalTrials.gov registry entry for NCT03596073 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topical Calcipotriene Ointment is the first listed.
NCT03596073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596073 about?
NCT03596073 is a clinical study titled "Topical Calcipotriene Treatment for Breast Cancer Immunoprevention". This research study is studying a topical ointment called calcipotriene to see if it can stimulate the immune cells against the breast lesion in ways that would prevent its recurrence after surgical removal
What is the current status of trial NCT03596073?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2018-11-07. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT03596073?
The interventions under investigation include: Topical Calcipotriene Ointment (DRUG), Topical Vaseline (OTHER).
Who is sponsoring clinical trial NCT03596073?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.